TSXV:BTI.H - Post by User
Comment by
narmacon Dec 13, 2022 2:51pm
119 Views
Post# 35169202
RE:RE:RE:RE:This Will Be Interesting
RE:RE:RE:RE:This Will Be Interesting ID | Technology | API | Therapeutic Area | Administration | Formulation | Pre-clinical | Phase 1 | Phase 2 | Partner |
|
MTD211 | Q-Sphera™ | Brexpiprazole | Schizophrenia, MDD | Long Acting Injectable | | | | | |
MTD219 | Q-Sphera™ | Tacrolimus | Prophylaxis, transplant rejection | Long Acting injectable | | | | | |
MTX213 | Q-Sphera™ | undisclosed | undisclosed | Long Acting Injectable | | | | | Janssen |
MTX223 | Q-Sphera™ | undisclosed | undisclosed | Long Acting Injectable | | | | | Janssen |
MTX114 | MidaCore™ | Methotrexate | Psoriasis | Topical | | | | | |
MTX110 | MidaSolve | Panobinostat | Glioblastoma | Direct to tumour via CED | | | | | |
MTX110 | MidaSolve | Panobinostat | Brain Cancer in Children (DIPG) | Direct to tumour via CED | | | | | |
MTX110 | MidaSolve | Panobinostat | Medulloblastoma | Direct to tumour | | | | | |